Authors
Yanhui Ma, Mingling Wang, Kexin Zhang, Fangbing Ren, Yuqun Wang, Wenqiang Zhang, Chengxia Kan, Fang Han, Hongxi Sun, Xiaodong Sun
Published in
Current cancer drug targets. Nov 12, 2026. Epub Nov 12, 2026.
Abstract
Following publication of the article entitled "Targeting Glutamine Metabolic Reprogramming in Pancreatic Cancer: Cur-rent Insights and Future Directions" [1], certain phrases and expressions were identified that were unclear or inconsistent with established scientific terminology. To ensure the accuracy and clarity of the published record, these expressions have been corrected using appropriate terminology that more accurately conveys the intended scientific meaning. These corrections are limited to the wording and terminology of the affected passages and do not alter the data, results, scientific interpretations, or conclusions of the article. The specific corrections are provided below: Section, Abstract, Original text: However, some studies have shown that inhibitors of this pathway can sensitize PC cells to chemotherapeutic agents, and this synergistic effect provides new insights into the combination therapy for PC. Corrected text: However, some studies have shown that inhibitors of this pathway can sensitize PC cells to chemotherapeutic agents, and this synergistic effect provides new opportunities for developing combination therapies for PC treatment. The original article has been updated accordingly. This corrigendum is published to maintain transparency and accuracy of the scholarly record. The corrected version of the article is available online at: https://www.eurekaselect.com/article/146023 The authors regret these errors and apologise for any inconvenience they may have caused.
PMID:
43023373
Bibliographic data and abstract were imported from PubMed on 13 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 7
- Comments 0